UNSPSC 51332501: Haloperidol

This classification denotes a butyrophenone with the molecular formula C21H23ClFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J6292F8L3D, chemically known as 1-butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- but generally known as haloperidol, which bears US NIH Compound Identifier 3559. European Medicines Agency schedules Haloperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08005MIG. The term HALOPERIDOL is an International Non-Proprietary Name.

UNSPSC 51332501 Haloperidol is a Commodity code that covers pharmaceutical products used in mental health and emergency medical treatment. State and local governments procure haloperidol and related antipsychotic medications through this code to support public health facilities, community health centers, emergency services, and correctional institutions. The code encompasses both branded and generic formulations of haloperidol in various delivery forms and dosages. Procuring jurisdictions include county health departments, municipal community health systems, state corrections and mental health agencies, and specialized public health districts. Vendors typically supply through standing supply agreements or competitive bid processes, with contract terms commonly including quarterly or annual deliveries, compliance with pharmaceutical handling and storage requirements, and adherence to federal regulations governing controlled-substance and non-controlled medication distribution.

The most recent documented opportunity shows limited direct activity under this specific code. A Seminole County, Florida IFB (IFB60459723LAS), posted June 30, 2026, sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023—though the haloperidol code itself does not appear to align with that solicitation's scope, which focuses on opioid-reversal agents and drug disposal rather than antipsychotic pharmaceuticals. The mismatch suggests either a tagging error or that this code sees limited recent procurement activity in the monitored state and local market. No other representative haloperidol-specific opportunities appear in the recent records. Firms pursuing this code should monitor county public health departments and state mental health agencies in Florida and other high-population states, though current visibility into active opportunities remains sparse.